6-Isopropyl-[1,2,4]triazolo[1,5-a]pyrimidine | 85599-29-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 6-Isopropyl-[1,2,4]triazolo[1,5-a]pyrimidine
• 英文别名: 6-propan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine
• CAS: 85599-29-7
• 化学式: C₈H₁₀N₄
• 分子量: 162.194
• InChiKey: NYYSKDQXYLVTRZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基-1,2,4-三氮唑 、 3-Ethoxy-2-isopropylacrolein 以82%的产率得到
  参考文献：
  名称：

  KUENSTLINGER, M.;BREITMAIER, E., SYNTHESIS, BRD, 1983, N 1, 44-47

  摘要：

  DOI：

文献信息

• Substituted heteroaryl compounds and methods of use
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：US10683297B2

  公开（公告）日：2020-06-16

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新型杂芳基化合物、药物可接受盐及其制剂。它们可用于预防、控制、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含此类化合物的药学上可接受的组合物，以及使用该组合物治疗蛋白激酶介导的疾病的方法。
• Amide substituted indole compounds useful as TLR inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11420973B2

  公开（公告）日：2022-08-23

  N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  其中 G、L2、R1、R5、R9、R10 和 n 在本文中定义。还公开了使用此类化合物作为通过 Toll 样受体 7 或 8 或 9 信号转导的抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
• 6-azaindole compounds
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11427580B2

  公开（公告）日：2022-08-30

  Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  公开了式 (I) N-氧化物化合物或其盐类，其中 A、G、R1、R5 和 n 在本文中定义。还公开了使用此类化合物作为通过 Toll 样受体 7 或 8 或 9 信号转导的抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗炎症和自身免疫性疾病。
• Kuenstlinger, M.; Breitmaier, E., Synthesis, 1983, # 1, p. 44 - 47
  作者：Kuenstlinger, M.、Breitmaier, E.

  DOI：——

  日期：——
• INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US20160304516A1

  公开（公告）日：2016-10-20

  The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.